SciSparc Ltd. (NASDAQ: SPRC), a clinical-stage pharmaceutical company, reported a new Phase IIb trial of SCI-110, a proprietary THC-based medication for Tourette Syndrome (TS) treatment.

Global Collaboration for TS Advancements

Spanning across renowned institutions such as Yale University, Tel Aviv Sourasky Medical Center and Hannover Medical School, the trial operates under the regulations of the Food and Drug Administration, BfArM and Israeli Ministry of Health.

Addressing a significant gap in TS management, SCI-110 combines FDA-approved synthetic THC (Dronabinol) with …

Full story available on

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.